Allergan
Founded in 1948, Allergan became a public company in 1970 and merged with SmithKline Beecham in 1980. It became independent again in 1989. Allergan’s research interests today include: glaucoma, retinal disease, dry eye, pain, movement disorders, retinoid technology, psoriasis, acne, photo-damage, metabolic disease and cancer.[1]
In 2006, Allergan was ranked 37th in the Top 50 pharmaceutical companies worldwide, with 2005 Global Sales of $2.32 and a Research and Design spend of $387M. [2]. Allergan operates in over 100 countries and has approximately 7,000 employees worldwide. Allergan markets several leading pharmaceutical products including BOTOX.
Allergan Holdings Limited and Allergan Limited are UK subsidiaries of Allergan, Inc.[3]
The Allergan Foundation is an offshoot of Allergan Inc. Since 1998 the Allergan Foundation has given grants of approximately $12M to the arts, civic programs, education and health and human services.
References
- ↑ http://www.allergan.co.uk/careers/culture.htm (Allergan Careers Information)
- ↑ Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138
- ↑ http://sec.edgar-online.com/2004/03/05/0000892569-04-000307/Section36.asp (EDGARonline)
